Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SpyGlass Pharma, Inc. Director's Dealing 2026

Feb 11, 2026

51541_dirs_2026-02-11_1f77b75e-ed5d-4a28-9c6e-1d490dc0500d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SpyGlass Pharma, Inc. (SGP)
CIK: 0001778922
Period of Report: 2026-02-09

Reporting Person: SANDELL SCOTT D (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2026-02-09 Common Stock C 1619240 Acquired 1619240 Indirect
2026-02-09 Common Stock C 1370168 Acquired 2989408 Indirect
2026-02-09 Common Stock C 1370168 Acquired 4359576 Indirect
2026-02-09 Common Stock C 737962 Acquired 5097538 Indirect
2026-02-09 Common Stock P 937500 $16.00 Acquired 6035038 Indirect
2026-02-09 Common Stock C 954990 Acquired 954990 Indirect
2026-02-09 Common Stock C 402273 Acquired 1357263 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2026-02-09 Series B Preferred Stock $ C 1619240 Disposed Common Stock (1619240) Indirect
2026-02-09 Series C-1 Preferred Stock $ C 1370168 Disposed Common Stock (1370168) Indirect
2026-02-09 Series C-2 Preferred Stock $ C 1370168 Disposed Common Stock (1370168) Indirect
2026-02-09 Series D Preferred Stock $ C 737962 Disposed Common Stock (737962) Indirect
2026-02-09 Series A Preferred Stock $ C 954990 Disposed Common Stock (954990) Indirect
2026-02-09 Series B Preferred Stock $ C 402273 Disposed Common Stock (402273) Indirect

Footnotes

F1: All shares of the preferred stock, par value $0.00001 per share, of the Issuer automatically converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.00001 per share ("Common Stock"), prior to the closing of the Issuer's initial public offering of its Common Stock on February 9, 2026.

F2: The Reporting Person is a manager of NEA 17 GP, LLC, which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of New Enterprise Associates 17, L.P. ("NEA 17"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

F3: The Reporting Person is a manager of NEA 16 GP, LLC, which is the sole general partner of NEA Partners 16, L.P. ("NEA Partners 16"). NEA Partners 16 is the sole general partner of New Enterprise Associates 16, L.P. ("NEA 16"), the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Exchange Act or otherwise of such portion of the securities held by NEA 16 in which the Reporting Person has no pecuniary interest.